The invention relates to a method for adding a compound (A) to an H-functional starting compound (BH) in the presence of a catalyst, wherein the at least one compound (A) is selected from at least one group consisting of alkylene oxide (A-1), lactone (A-2), lactide (A-3), cyclic acetal (A-4), lactam (A-5), cyclic anhydride (A-6) and oxygen-containing heterocyclic compound (A-7) different from (A-1), (A-2), (A-3), (A-4) and (A-6), wherein the catalyst comprises an organic, n-protic Brnsted acid (C), wherein n2 and is an element of the natural numbers and the degree of protolysis D is 0<D<n, with n as the maximum number of transferable protons and D as the calculated proton fraction of the organic, n-protic Brnsted acid (C). The invention further relates to an n-protic Brnsted acid (C) having a degree of protolysis D of 0<D<n, wherein n is the maximum number of transferable protons, with n=2, 3 or 4, and D is the calculated proton fraction of the organic, n-protic Brnsted acid (C).

The subject of the present invention is a weakly corrosive and weakly coloured sulfonic acid, with an APHA colour index of less than 20, comprising chlorides and nitrites in a chloride/sulfonic acid molar ratio of between 1 ppm and 200 ppm, and a nitrite/sulfonic acid molar ratio of between 200 ppm and 6000 ppm, limits inclusive.

The subject of the present invention is a weakly corrosive and weakly coloured sulfonic acid, with an APHA colour index of less than 20, comprising chlorides and nitrites in a chloride/sulfonic acid molar ratio of between 1 ppm and 200 ppm, and a nitrite/sulfonic acid molar ratio of between 200 ppm and 6000 ppm, limits inclusive.

The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.

The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.

The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl.

The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W, X, Y, and Z are each as defined in the specification:

##STR00001##

The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl.

The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W, X, Y, and Z are each as defined in the specification:

##STR00001##

The present invention provides novel pharmaceutically acceptable salts of a morpholine derivative, including a malate, a tartrate, a hydrochloride, an acetate, and a naphthalene disulfonate thereof, wherein the tartrate has 3 crystal salt forms: crystal form A, crystal form B and dihydrate; the malate, the hydrochloride, and the acetate each have one crystal salt form; the naphthalene disulfonate is amorphous. When compared to the known morpholine derivative free base, the present invention has one or more improved properties, e.g., a better crystalline state, greatly improved water solubility, light stability and thermal stability, etc. The present invention further provides preparation methods for the salts of morpholine derivative and the crystal forms thereof, pharmaceutical compositions and use thereof.